<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01630200</url>
  </required_header>
  <id_info>
    <org_study_id>ELASTIC2011</org_study_id>
    <nct_id>NCT01630200</nct_id>
  </id_info>
  <brief_title>Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>ELASTIC</acronym>
  <official_title>Effects of ROFLUMILAST on Markers of Subclinical Atherosclerosis In Stable COPD; the ELASTIC-trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic obstructive pulmonary disease is associated with a low grade systemic inflammatory
      process. Systemic inflammation is hypothesized to maintain cardiovascular morbidity and
      mortality in COPD. Early changes of vascular integrity can be detected via markers of
      subclinical atherosclerosis.

      Selective Inhibition of phosphodiesterase subtype 4 describes a promising therapeutic option
      in COPD with beneficial impact on lung function and exacerbation rate. Moreover, an
      anti-inflammatory effect of phosphodiesterase-4 inhibition was confirmed by recent data.

      The aim of this study is to assess the effects of the phosphodiesterase-4 inhibitor
      Roflumilast on firstly surrogates of subclinical atherosclerosis and secondly markers of
      systemic inflammation in the peripheral circulation of patients with stable chronic
      obstructive pulmonary disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Carotid Femoral-Pulse Wave Velocity at Month 6</measure>
    <time_frame>baseline, month 6</time_frame>
    <description>Carotid femoral-Pulse Wave Velocity (cf-PWV) will be measured non-invasively via applanation tonometry (AtCor Medical, Sydney, Australia). Wave propagation time will be calculated by the system software, using an ECG-gated reference frame. Aortic PWV is defined as the distance between two recording sites (i.e. common carotid- and femoral artery) divided by the wave propagation time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Reactive Hyperemia Index at Month 6</measure>
    <time_frame>baseline, month 6</time_frame>
    <description>Endothelial dysfunction will be assessed by Flow Mediated Dilation via the Endopat device. This validated system measures the pulse wave amplitudes at the tip of both index fingers. The dominant arm will be occluded for 5 minutes by a sphygmomanometric cuff. After cuff deflation the pulse wave amplitude will be assessed to finally calculate the ratio of pulse wave amplitude before and after cuff-induced hyperemia. The so called reactive hyperemia index represents endothelial dysfunction at the level of conduit as well as resistance vessels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Augmentation Index at Month 6</measure>
    <time_frame>baseline, month 6</time_frame>
    <description>The curve of the peripheral pressure wave will be recorded from the radial artery. Augmentation index (Aix) will be calculated from the generated central aortic pressure waveform via pulse wave analysis function. To correct for respective influences, Aix will be adjusted for a heart rate of 75 bpm. Appropriate intra observer validity will be assured via an operator index ≥ 80.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Matrix Metalloproteinase-9</measure>
    <time_frame>baseline, month 6</time_frame>
    <description>Circulating levels of Matrix Metalloproteinase-9 (MMP-9) will be quantified from venous blood samples via Enzyme-linked Immunosorbent Assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Asymmetric Dimethylarginine at Month 6</measure>
    <time_frame>baseline, month 6</time_frame>
    <description>Circulating levels of Asymmetric dimethylarginine (ADMA) will be quantified from venous blood samples via Enzyme-linked Immunosorbent Assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tumor Necrosis Factor-alpha at Month 6</measure>
    <time_frame>baseline, month 6</time_frame>
    <description>Circulating levels of Tumor Necrosis Factor-alpha (TNF-alpha) will be quantified from venous blood samples via Enzyme-linked Immunosorbent Assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in 1 Second at Month 6</measure>
    <time_frame>baseline, month 6</time_frame>
    <description>Forced Expiratory Volume in 1 second (FEV1) will be measured via standardized Spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 6-Minute Walk Test at Month 6</measure>
    <time_frame>baseline, month 6</time_frame>
    <description>6-Minute Walk Test (6MWT) will be assessed to quantify functional exercise capacity following the standardized protocol of the American Thoracic Society</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in COPD Assessment Test at Month 6</measure>
    <time_frame>baseline, month 6</time_frame>
    <description>COPD Assessment Test (CAT) will be assessed to quantify patients disease related symptoms and to measure the impact of COPD on a patient's life, and how this changes over time. CAT is a standardised and validated patient questionaire comprising 8 distinct questions about different COPD-related symptoms. Each symptom is quantified by the patient on a numeric scale ranging from 0 to 5. Each symptom gives a number of points quantified as interval data without decimal places. The 8 different numbers of points are added to a total number expressed as the final points of the CAT score. The minimum achievable number of points is 0 and the maximum achievable number of points is 40. Higher values provide high symptoms and worse outcome, lower values provide low symptoms and better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease and Allied Conditions</condition>
  <arm_group>
    <arm_group_label>Roflumilast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active arm including patients who receive the study drug (500µg Roflumilast once daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control arm including patients who receive the placebo tablet (once daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>Roflumilast coated tablet, 500µg oral application, once daily in the morning</description>
    <arm_group_label>Roflumilast</arm_group_label>
    <other_name>Daxas</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 40 years of age

          -  Smoking history of at least 10 pack years

          -  Chronic obstructive pulmonary disease at Global Initiative for Chronic Obstructive
             Lung Disease (GOLD) stage II - IV diagnosed according to standard criteria.

          -  History of at least one COPD exacerbation requiring systemic corticosteroid treatment
             or hospitalisation in the previous year

        Exclusion Criteria:

          -  Insufficient compliance to study medication (≤70% of tablets used) during 4 weeks
             run-in period

          -  History of acute exacerbation 4 weeks prior to run-in period

          -  Diagnosis of alpha-1-antitrypsin deficiency

          -  Diagnosis of asthma

          -  Acute respiratory infections (e.g. pneumonia)

          -  Severe acute infectious diseases (e.g. active hepatitis, HIV)

          -  Lung cancer

          -  Bronchiectasis

          -  Interstitial lung disease

          -  Any other relevant lung disease

          -  Acute myocardial infarction

          -  Systolic left ventricular dysfunction

          -  Congestive heart failure New York Heart Association Functional Classification (NYHA)
             severity grade IV

          -  Haemodynamically significant cardiac arrhythmias or heart valve deformations

          -  Peripheral arterial occlusive disease

          -  Acute or chronic renal/hepatic failure

          -  Active malignancy

          -  Autoimmune disease

          -  Pregnant or breastfeeding women

          -  Women no using or not willing to use adequate contraceptive measures for the duration
             of the trial

          -  Hypersensitivity to study medication or placebo

          -  Severe psychiatric or neurological disorders or history of depression associated with
             suicidal ideation or behaviour

          -  Galactose intolerance, lactase insufficiency or glucose-galactose malabsorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Otto C Burghuber, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department for Respiratory and Critical Care Medicine, Otto Wagner Hospital, Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deparment for Respiratory and Critical Care Medicine, Otto Wangner Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 4, 2012</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <results_first_submitted>August 26, 2017</results_first_submitted>
  <results_first_submitted_qc>January 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2019</results_first_posted>
  <last_update_submitted>January 14, 2019</last_update_submitted>
  <last_update_submitted_qc>January 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>comorbidity</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>roflumilast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from the Department of Respiratory and Critical Care Medicine in the Otto Wagner Hospital in Vienna and supporting centres (hospitals, outpatient clinics, respiratory specialists).</recruitment_details>
      <pre_assignment_details>After inclusion, patients entered a 4 week, single-masked run-in period with placebo application. Given sufficient compliance to medication (≥70% of tablets) patients were randomized to receive either the study drug (Roflumilast 500 μg) or placebo in a double-masked manner.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Roflumilast</title>
          <description>Active arm including patients who receive the study drug (500µg Roflumilast once daily)
Roflumilast: Roflumilast coated tablet, 500µg oral application, once daily in the morning</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Control arm including patients who receive the placebo tablet (once daily)
Placebo: Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Roflumilast</title>
          <description>Active arm including patients who receive the study drug (500µg Roflumilast once daily)
Roflumilast: Roflumilast coated tablet, 500µg oral application, once daily in the morning</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Control arm including patients who receive the placebo tablet (once daily)
Placebo: Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" lower_limit="61" upper_limit="69.5"/>
                    <measurement group_id="B2" value="64.5" lower_limit="56" upper_limit="72"/>
                    <measurement group_id="B3" value="64.5" lower_limit="57" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Carotid Femoral-Pulse Wave Velocity at Month 6</title>
        <description>Carotid femoral-Pulse Wave Velocity (cf-PWV) will be measured non-invasively via applanation tonometry (AtCor Medical, Sydney, Australia). Wave propagation time will be calculated by the system software, using an ECG-gated reference frame. Aortic PWV is defined as the distance between two recording sites (i.e. common carotid- and femoral artery) divided by the wave propagation time.</description>
        <time_frame>baseline, month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>Active arm including patients who receive the study drug (500µg Roflumilast once daily)
Roflumilast: Roflumilast coated tablet, 500µg oral application, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control arm including patients who receive the placebo tablet (once daily)
Placebo: Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Carotid Femoral-Pulse Wave Velocity at Month 6</title>
          <description>Carotid femoral-Pulse Wave Velocity (cf-PWV) will be measured non-invasively via applanation tonometry (AtCor Medical, Sydney, Australia). Wave propagation time will be calculated by the system software, using an ECG-gated reference frame. Aortic PWV is defined as the distance between two recording sites (i.e. common carotid- and femoral artery) divided by the wave propagation time.</description>
          <units>meters per second (m/s)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="0.98" upper_limit="1.17"/>
                    <measurement group_id="O2" value="0.99" lower_limit="0.91" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Reactive Hyperemia Index at Month 6</title>
        <description>Endothelial dysfunction will be assessed by Flow Mediated Dilation via the Endopat device. This validated system measures the pulse wave amplitudes at the tip of both index fingers. The dominant arm will be occluded for 5 minutes by a sphygmomanometric cuff. After cuff deflation the pulse wave amplitude will be assessed to finally calculate the ratio of pulse wave amplitude before and after cuff-induced hyperemia. The so called reactive hyperemia index represents endothelial dysfunction at the level of conduit as well as resistance vessels.</description>
        <time_frame>baseline, month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>Active arm including patients who receive the study drug (500µg Roflumilast once daily)
Roflumilast: Roflumilast coated tablet, 500µg oral application, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control arm including patients who receive the placebo tablet (once daily)
Placebo: Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Reactive Hyperemia Index at Month 6</title>
          <description>Endothelial dysfunction will be assessed by Flow Mediated Dilation via the Endopat device. This validated system measures the pulse wave amplitudes at the tip of both index fingers. The dominant arm will be occluded for 5 minutes by a sphygmomanometric cuff. After cuff deflation the pulse wave amplitude will be assessed to finally calculate the ratio of pulse wave amplitude before and after cuff-induced hyperemia. The so called reactive hyperemia index represents endothelial dysfunction at the level of conduit as well as resistance vessels.</description>
          <units>Index</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.88" upper_limit="1.11"/>
                    <measurement group_id="O2" value="1.02" lower_limit="0.91" upper_limit="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Augmentation Index at Month 6</title>
        <description>The curve of the peripheral pressure wave will be recorded from the radial artery. Augmentation index (Aix) will be calculated from the generated central aortic pressure waveform via pulse wave analysis function. To correct for respective influences, Aix will be adjusted for a heart rate of 75 bpm. Appropriate intra observer validity will be assured via an operator index ≥ 80.</description>
        <time_frame>baseline, month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>Active arm including patients who receive the study drug (500µg Roflumilast once daily)
Roflumilast: Roflumilast coated tablet, 500µg oral application, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control arm including patients who receive the placebo tablet (once daily)
Placebo: Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Augmentation Index at Month 6</title>
          <description>The curve of the peripheral pressure wave will be recorded from the radial artery. Augmentation index (Aix) will be calculated from the generated central aortic pressure waveform via pulse wave analysis function. To correct for respective influences, Aix will be adjusted for a heart rate of 75 bpm. Appropriate intra observer validity will be assured via an operator index ≥ 80.</description>
          <units>Index</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.11" lower_limit="-5.33" upper_limit="3.11"/>
                    <measurement group_id="O2" value="-1.99" lower_limit="-6.12" upper_limit="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Matrix Metalloproteinase-9</title>
        <description>Circulating levels of Matrix Metalloproteinase-9 (MMP-9) will be quantified from venous blood samples via Enzyme-linked Immunosorbent Assay</description>
        <time_frame>baseline, month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>Active arm including patients who receive the study drug (500µg Roflumilast once daily)
Roflumilast: Roflumilast coated tablet, 500µg oral application, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control arm including patients who receive the placebo tablet (once daily)
Placebo: Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Matrix Metalloproteinase-9</title>
          <description>Circulating levels of Matrix Metalloproteinase-9 (MMP-9) will be quantified from venous blood samples via Enzyme-linked Immunosorbent Assay</description>
          <units>ng/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-143" lower_limit="-370" upper_limit="84.6"/>
                    <measurement group_id="O2" value="-77" lower_limit="-301" upper_limit="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Asymmetric Dimethylarginine at Month 6</title>
        <description>Circulating levels of Asymmetric dimethylarginine (ADMA) will be quantified from venous blood samples via Enzyme-linked Immunosorbent Assay</description>
        <time_frame>baseline, month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>Active arm including patients who receive the study drug (500µg Roflumilast once daily)
Roflumilast: Roflumilast coated tablet, 500µg oral application, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control arm including patients who receive the placebo tablet (once daily)
Placebo: Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Asymmetric Dimethylarginine at Month 6</title>
          <description>Circulating levels of Asymmetric dimethylarginine (ADMA) will be quantified from venous blood samples via Enzyme-linked Immunosorbent Assay</description>
          <units>µmol/l</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.88" upper_limit="1.06"/>
                    <measurement group_id="O2" value="0.91" lower_limit="0.83" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tumor Necrosis Factor-alpha at Month 6</title>
        <description>Circulating levels of Tumor Necrosis Factor-alpha (TNF-alpha) will be quantified from venous blood samples via Enzyme-linked Immunosorbent Assay</description>
        <time_frame>baseline, month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>Active arm including patients who receive the study drug (500µg Roflumilast once daily)
Roflumilast: Roflumilast coated tablet, 500µg oral application, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control arm including patients who receive the placebo tablet (once daily)
Placebo: Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tumor Necrosis Factor-alpha at Month 6</title>
          <description>Circulating levels of Tumor Necrosis Factor-alpha (TNF-alpha) will be quantified from venous blood samples via Enzyme-linked Immunosorbent Assay</description>
          <units>pg/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.82" upper_limit="1.08"/>
                    <measurement group_id="O2" value="1.06" lower_limit="0.92" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Expiratory Volume in 1 Second at Month 6</title>
        <description>Forced Expiratory Volume in 1 second (FEV1) will be measured via standardized Spirometry</description>
        <time_frame>baseline, month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>Active arm including patients who receive the study drug (500µg Roflumilast once daily)
Roflumilast: Roflumilast coated tablet, 500µg oral application, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control arm including patients who receive the placebo tablet (once daily)
Placebo: Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Volume in 1 Second at Month 6</title>
          <description>Forced Expiratory Volume in 1 second (FEV1) will be measured via standardized Spirometry</description>
          <units>% predicted</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.96" upper_limit="1.08"/>
                    <measurement group_id="O2" value="1.01" lower_limit="0.96" upper_limit="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 6-Minute Walk Test at Month 6</title>
        <description>6-Minute Walk Test (6MWT) will be assessed to quantify functional exercise capacity following the standardized protocol of the American Thoracic Society</description>
        <time_frame>baseline, month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>Active arm including patients who receive the study drug (500µg Roflumilast once daily)
Roflumilast: Roflumilast coated tablet, 500µg oral application, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control arm including patients who receive the placebo tablet (once daily)
Placebo: Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 6-Minute Walk Test at Month 6</title>
          <description>6-Minute Walk Test (6MWT) will be assessed to quantify functional exercise capacity following the standardized protocol of the American Thoracic Society</description>
          <units>meters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2" lower_limit="18.3" upper_limit="100"/>
                    <measurement group_id="O2" value="0.69" lower_limit="-39.7" upper_limit="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in COPD Assessment Test at Month 6</title>
        <description>COPD Assessment Test (CAT) will be assessed to quantify patients disease related symptoms and to measure the impact of COPD on a patient's life, and how this changes over time. CAT is a standardised and validated patient questionaire comprising 8 distinct questions about different COPD-related symptoms. Each symptom is quantified by the patient on a numeric scale ranging from 0 to 5. Each symptom gives a number of points quantified as interval data without decimal places. The 8 different numbers of points are added to a total number expressed as the final points of the CAT score. The minimum achievable number of points is 0 and the maximum achievable number of points is 40. Higher values provide high symptoms and worse outcome, lower values provide low symptoms and better outcome.</description>
        <time_frame>baseline, month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>Active arm including patients who receive the study drug (500µg Roflumilast once daily)
Roflumilast: Roflumilast coated tablet, 500µg oral application, once daily in the morning</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Control arm including patients who receive the placebo tablet (once daily)
Placebo: Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in COPD Assessment Test at Month 6</title>
          <description>COPD Assessment Test (CAT) will be assessed to quantify patients disease related symptoms and to measure the impact of COPD on a patient's life, and how this changes over time. CAT is a standardised and validated patient questionaire comprising 8 distinct questions about different COPD-related symptoms. Each symptom is quantified by the patient on a numeric scale ranging from 0 to 5. Each symptom gives a number of points quantified as interval data without decimal places. The 8 different numbers of points are added to a total number expressed as the final points of the CAT score. The minimum achievable number of points is 0 and the maximum achievable number of points is 40. Higher values provide high symptoms and worse outcome, lower values provide low symptoms and better outcome.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" lower_limit="-1.36" upper_limit="2.19"/>
                    <measurement group_id="O2" value="1.2" lower_limit="-0.57" upper_limit="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Roflumilast</title>
          <description>Active arm including patients who receive the study drug (500µg Roflumilast once daily)
Roflumilast: Roflumilast coated tablet, 500µg oral application, once daily in the morning</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Control arm including patients who receive the placebo tablet (once daily)
Placebo: Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Polypectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Death (unknown origin)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchoscopic lung volume reduction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pulmonary nodule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Bronchoscopy for bronchiectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypercapnic decompensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Diabetic vasculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Obstipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenca</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cramps in upper/lower extremities</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Herniated vertebral disc</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E2" events="24" subjects_affected="16" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Matthias Urban</name_or_title>
      <organization>Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology</organization>
      <phone>+43(0)6508125980</phone>
      <email>matthias.urban1@gmx.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

